Clinical data
Routes of
Oral, Insufflation
ATC code none
Legal status
Legal status
CAS Number 125903-69-7 N
PubChem (CID) 23844155
ChemSpider 23108678 YesY
Chemical and physical data
Formula C11H16FNO2
Molar mass 213.25 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

2,5-Dimethoxy-4-fluoroamphetamine (DOF) is a psychedelic drug of the phenethylamine and amphetamine classes. Alexander Shulgin briefly describes DOF in his book PiHKAL:[1]

Animal studies that have compared DOF to the highly potent DOI and DOB imply that the human activity will be some four to six times less than these two heavier halide analogues.[2] As of the present time, no human trials of DOF have been made.

DOF showed some stimulating effects but no psychedelic activity at 3x6 mg (spaced by 1h, each) in humans.[3] Trachsel further suspected that the molar refraction of the important 4-substituent in DOF and 2C-F may be too low to activate the 5-HT2A receptor sufficiently.[4] DOF rather resembles the 4-unsubstituted 2,5-dimethoxyamphetamine than DOC, DOB or DOI.[5][6][7]

See also


  1. Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. United States: Transform Press. p. 978. ISBN 0-9630096-0-5.
  2. Glennon RA, Young R, Benington F, Morin RD (October 1982). "Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane". Journal of Medicinal Chemistry. 25 (10): 1163–8. doi:10.1021/jm00352a013. PMID 7143352.
  3. D.E. Nichols (1991). Biochemistry and Physiology of Substance Abuse, Vol. III. Boca Raton, FL: CRC Press.
  4. Daniel Trachsel (July 2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7-8): 577–590. doi:10.1002/dta.413. PMID 22374819.
  5. David E. Nichols; Stewart Frescas; Danuta Marona-Lewicka; Xuemei Huang; Bryan L. Roth; Gary A. Gudelsky; J. Frank Nash (December 1994). "1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.". Journal of Medicinal Chemistry. 37 (25): 4346–4351. doi:10.1021/jm00051a011. PMID 7996545.
  6. Richard A. Glennon (1991). "Discriminative stimulus properties of hallucinogens and related designer drugs.". NIDA Research Monograph. 116: 25–44. PMID 1369672.
  7. Johnson MP; Hoffman AJ; Nichols DE; Mathis CA. (December 1987). "Binding to the serotonin 5-HT2 receptor by the enantiomers of 125I-DOI.". Neuropharmacology. 26 (12): 1803–1806. doi:10.1016/0028-3908(87)90138-9. PMID 3437942.

External links

This article is issued from Wikipedia - version of the 11/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.